These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17447930)

  • 1. Joint modeling of progression of HIV resistance mutations measured with uncertainty and failure time data.
    Hu C; De Gruttola V
    Biometrics; 2007 Mar; 63(1):60-8. PubMed ID: 17447930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accommodating uncertainty in a tree set for function estimation.
    Healy BC; DeGruttola VG; Hu C
    Stat Appl Genet Mol Biol; 2008; 7(1):Article5. PubMed ID: 18312210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resampling-based multiple testing methods with covariate adjustment: application to investigation of antiretroviral drug susceptibility.
    Yang Y; Degruttola V
    Biometrics; 2008 Jun; 64(2):329-36. PubMed ID: 17900313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.
    Hoffmann C; Minkah N; Leipzig J; Wang G; Arens MQ; Tebas P; Bushman FD
    Nucleic Acids Res; 2007; 35(13):e91. PubMed ID: 17576693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of artificial neural networks to predict virological response to combination HIV therapy.
    Larder B; Wang D; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; Monforte AD; Torti C; Zazzi M; Lane C
    Antivir Ther; 2007; 12(1):15-24. PubMed ID: 17503743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses.
    Healy B; Degruttola V
    Biostatistics; 2007 Apr; 8(2):438-52. PubMed ID: 16940036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Historical resistance profile helps to predict salvage failure.
    Zaccarelli M; Lorenzini P; Ceccherini-Silberstein F; Tozzi V; Forbici F; Gori C; Trotta MP; Boumis E; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2009; 14(2):285-91. PubMed ID: 19430103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
    Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
    Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
    Verhofstede C; Van Wanzeele F; Van Der Gucht B; Pelgrom J; Vandekerckhove L; Plum J; Vogelaers D
    J Med Virol; 2007 Sep; 79(9):1254-60. PubMed ID: 17607772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
    Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
    AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model selection for mixtures of mutagenetic trees.
    Yin J; Beerenwinkel N; Rahnenführer J; Lengauer T
    Stat Appl Genet Mol Biol; 2006; 5():Article17. PubMed ID: 17049028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
    Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations.
    Healy B; De Gruttola V; Pagano M
    Biometrics; 2007 Sep; 63(3):742-50. PubMed ID: 17403101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.